PATENT CLAIM ANALYSIS

Application Number: 15900570
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-10
Patent Classification: ["514", "051000"]

Abstract:
This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.

Claim (Index 1):
A method for treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of\n a compound of formula I: or a salt thereof, wherein: A is a 3- to 10-membered aromatic or non-aromatic ring having up to 5 heteroatoms independently selected from N, O, S, SO, or SO 2 , wherein the aromatic or non-aromatic ring is independently and optionally substituted with one or more R 7 ; X is independently selected from \u2014O\u2014, \u2014S\u2014, \u2014N(R 5 )\u2014 and a (C1-C3)-aliphatic group independently and optionally substituted with one or more R 4 ; Y is a bond or a (C1-C5)-aliphatic group independently and optionally substituted with one or more R 4 ; Z and W are each independently selected from \u2550O, \u2550S, \u2550N(R 5 ), and \u2550NOR 5 ; R 1  is selected from:\n \u2014H, halogen, \u2014OR 5 , \u2014CN, \u2014CF 3 , \u2014OCF 3  and a (C1-C6)-aliphatic group optionally substituted with one or more R 7 ; \n R 2  and R 3  are each independently selected from \u2014OR 5 , \u2014SR 5 , \u2014NR 5 R 6 , \u2014OC(O)R 5 , \u2014OC(O)NR 5 R 6 , and \u2014OC(O)OR 5 ; each occurrence of R 4  is independently selected from:\n halogen, \u2014OR 5 , \u2014NO 2 , \u2014CN, \u2014CF 3 , \u2014OCF 3 , \u2014R 5 , 1,2-methylenedioxy, 1,2-ethylenedioxy, \u2014N(R 5 ) 2 , \u2014SR 5 , \u2014SOR 5 , \u2014SO 2 R 5 , \u2014SO 2 N(R 5 ) 2 , \u2014SO 3 R 5 , \u2014C(O)R 5 , \u2014C(O)C(O)R 5 , \u2014C(O)CH 2 C(O)R 5 , \u2014C(S)R 5 , \u2014C(S)OR 5 , \u2014C(O)OR 5 , \u2014C(O)C(O)OR 5 , \u2014C(O)C(O)N(R 5 ) 2 , \u2014OC(O)R 5 , \u2014C(O)N(R 5 ) 2 , \u2014OC(O)N(R 5 ) 2 , \u2014C(S)N(R 5 ) 2 , \u2014(CH 2 ) 0-2 NHC(O)R 5 , \u2014N(R 5 )N(R 5 )COR 5 , \u2014N(R 5 )N(R 5 )C(O)OR 5 , \u2014N(R 5 )N(R 5 )CON(R 5 ) 2 , \n \u2014N(R 5 )SO 2 R 5 , \u2014N(R 5 )SO 2 N(R 5 ) 2 , \u2014N(R 5 )C(O)OR 5 , \u2014N(R 5 )C(O)R 5 , \u2014N(R 5 )C(S)R 5 , \u2014N(R 5 )C(O)N(R 5 ) 2 , \u2014N(R 5 )C(S)N(R 5 ) 2 , \u2014N(COR 5 )COR 5 , \u2014N(OR 5 )R 5 , \u2014C(\u2550NH)N(R 5 ) 2 , \u2014C(O)N(OR 5 )R 5 , \u2014C(\u2550NOR 5 )R 5 , \u2014OP(O)(OR 5 ) 2 , \u2014P(O)(R 5 ) 2 , \u2014P(O)(OR 5 ) 2 , or \u2014P(O)(H)(OR 5 ); \n each occurrence of R 5  is independently selected from:\n H\u2014, \n (C1-C12)-aliphatic-, \n (C3-C10)-cycloalkyl- or -cycloalkenyl-, \n [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-, \n (C6-C10)-aryl-, \n (C6-C10)-aryl-(C1-C12)aliphatic-, \n (C3-C10)-heterocyclyl-, \n (C6-C10)-heterocyclyl-(C1-C12)aliphatic-, \n (C5-C10)-heteroaryl-, and \n (C5-C10)-heteroaryl-(C1-C12)-aliphatic-; \n wherein two R 5  groups bound to the same atom optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, O, S, SO, or SO 2 , wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl; and \n wherein each R 5  group is independently and optionally substituted with one or more R 7 ; \n R 6  is selected from:\n \u2014R 5 , \u2014C(O)R 5 , \u2014C(O)OR 5 , \u2014C(O)N(R 8 ) 2  and \u2014S(O) 2 R 5 ; \n each occurrence of R 7  is independently selected from:\n halogen, \u2014OR 8 , \u2014NO 2 , \u2014CN, \u2014CF 3 , \u2014OCF 3 , \u2014R 8 , oxo, thioxo, 1,2-methylenedioxy, 1,2-ethylenedioxy, \u2014N(R 8 ) 2 , \u2014SR 8 , \u2014SOR 8 , \u2014SO 2 R 8 , \u2014SO 2 N(R 8 ) 2 , \u2014SO 3 R 8 , \u2014C(O)R 8 , \u2014C(O)C(O)R 8 , \u2014C(O)CH 2 C(O)R 8 , \u2014C(S)R 8 , \u2014C(S)OR 8 , \u2014C(O)OR 8 , \u2014C(O)C(O)OR 8 , \u2014C(O)C(O)N(R 8 ) 2 , \u2014OC(O)R 8 , \u2014C(O)N(R 8 ) 2 , \u2014OC(O)N(R 8 ) 2 , \u2014C(S)N(R 8 ) 2 , \u2014(CH 2 ) 0-2 NHC(O)R 8 , \u2014N(R 8 )N(R 8 )COR 8 , \u2014N(R 8 )N(R 8 )C(O)OR 8 , \u2014N(R 8 )N(R 8 )CON(R 8 ) 2 , \n \u2014N(R 8 )SO 2 R 8 , \u2014N(R 8 )SO 2 N(R 8 ) 2 , \u2014N(R 8 )C(O)OR 8 , \u2014N(R 8 )C(O)R 8 , \u2014N(R 8 )C(S)R 8 , \u2014N(R 8 )C(O)N(R 8 ) 2 , \u2014N(R 8 )C(S)N(R 8 ) 2 , \u2014N(COR 8 )COR 8 , \u2014N(OR 8 )R 8 , \u2014C(\u2550NH)N(R 8 ) 2 , \u2014C(O)N(OR 8 )R 8 , \u2014C(\u2550NOR 8 )R 8 , \u2014OP(O)(OR 8 ) 2 , \u2014P(O)(R 8 ) 2 , \u2014P(O)(OR 8 ) 2 , or \u2014P(O)(H)(OR 8 ); and \n each occurrence of R 8  is independently selected from:\n H\u2014 and (C1-C6)-aliphatic.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 88.0
- Lexical Diversity: 1.98148
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14432104', '14039748', '14885773', '14775426', '14210333']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8439931230458063
- 35 USC 102 Novelty (BERT): 0.7053781366140912
- Combined Prediction Score: 0.8301316244026348
- Mean Citation Score: 714.7916899999999
- Max Citation Score: 737.1536
- Similarity Product: 734.1818244152067

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test